FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2315703663> ?p ?o ?g. }

• W2315703663 endingPage "83S" @default.
• W2315703663 startingPage "76S" @default.
• W2315703663 abstract "Moclobemide is a reversible and selective inhibitor of monoamine oxidase subtype A with a wide spectrum of antidepressant activity.To fully evaluate product safety, Roche Drug Safety has collected data on adverse events (AEs), regardless of causality, from all sources worldwide through the product development phase and after launch. This effort has included analyses of reports from clinical trials, regulatory authorities, the literature, observational studies, and the marketplace. Roche Drug Safety has also carefully examined all cases where moclobemide was taken in overdose, whether with or without other substances. This article presents the safety profile of the product after 3 years on world markets. In clinical trials, moclobemide appeared only slightly less well tolerated than placebo. In comparative trials, moclobemide was largely devoid of the anticholinergic effects associated with tricyclic antidepressants. To the end of June 1993, with an estimated 780,000 subjects exposed, AEs had been reported by less than 0.2% of users. The most frequently reported AEs were psychiatric, neurologic, and gastrointestinal disorders. Hepatobiliary AEs were rare, suggesting that moclobemide is largely devoid of hepatotoxic potential. Cardiovascular AEs reflected the prevalence of cardiovascular disease in the population treated. This safety profile is largely unchanged from those observed at 1 and 2 years postlaunch, when the estimated exposed populations were 168,000 and 328,000, respectively. It is of great significance that the fatal toxicity index of moclobemide is zero. A review of single-drug intoxications with moclobemide at doses of up to 20.55 g revealed no deaths due solely to moclobemide overdose. All patients recovered fully within 1 to 7 days without residual hepatic or cardiovascular toxicity. There is no evidence of an increased risk of suicidal behavior in users of moclobemide. Close compound monitoring through development and after launch has confirmed the safety of moclobemide in therapeutic doses and in overdose. (J Clin Psychopharmacol 1995;15[Suppl 2]:76S-83S)" @default.
• W2315703663 created "2016-06-24" @default.
• W2315703663 creator A5051931831 @default.
• W2315703663 creator A5070583832 @default.
• W2315703663 creator A5074048075 @default.
• W2315703663 date "1995-08-01" @default.
• W2315703663 modified "2023-10-16" @default.
• W2315703663 title "Moclobemide Safety" @default.
• W2315703663 cites W1976402477 @default.
• W2315703663 cites W1988043160 @default.
• W2315703663 cites W1997906496 @default.
• W2315703663 cites W2002378138 @default.
• W2315703663 cites W2008558030 @default.
• W2315703663 cites W2015283534 @default.
• W2315703663 cites W2016810594 @default.
• W2315703663 cites W2038532904 @default.
• W2315703663 cites W2040301373 @default.
• W2315703663 cites W2055663014 @default.
• W2315703663 cites W2058221420 @default.
• W2315703663 cites W2074986536 @default.
• W2315703663 cites W2075476000 @default.
• W2315703663 cites W2116386294 @default.
• W2315703663 cites W2320554816 @default.
• W2315703663 doi "https://doi.org/10.1097/00004714-199508001-00013" @default.
• W2315703663 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7593735" @default.
• W2315703663 hasPublicationYear "1995" @default.
• W2315703663 type Work @default.
• W2315703663 sameAs 2315703663 @default.
• W2315703663 citedByCount "25" @default.
• W2315703663 countsByYear W23157036632020 @default.
• W2315703663 countsByYear W23157036632021 @default.
• W2315703663 crossrefType "journal-article" @default.
• W2315703663 hasAuthorship W2315703663A5051931831 @default.
• W2315703663 hasAuthorship W2315703663A5070583832 @default.
• W2315703663 hasAuthorship W2315703663A5074048075 @default.
• W2315703663 hasConcept C126322002 @default.
• W2315703663 hasConcept C197934379 @default.
• W2315703663 hasConcept C2779177272 @default.
• W2315703663 hasConcept C2780237459 @default.
• W2315703663 hasConcept C2781161787 @default.
• W2315703663 hasConcept C71924100 @default.
• W2315703663 hasConcept C98274493 @default.
• W2315703663 hasConceptScore W2315703663C126322002 @default.
• W2315703663 hasConceptScore W2315703663C197934379 @default.
• W2315703663 hasConceptScore W2315703663C2779177272 @default.
• W2315703663 hasConceptScore W2315703663C2780237459 @default.
• W2315703663 hasConceptScore W2315703663C2781161787 @default.
• W2315703663 hasConceptScore W2315703663C71924100 @default.
• W2315703663 hasConceptScore W2315703663C98274493 @default.
• W2315703663 hasLocation W23157036631 @default.
• W2315703663 hasLocation W23157036632 @default.
• W2315703663 hasOpenAccess W2315703663 @default.
• W2315703663 hasPrimaryLocation W23157036631 @default.
• W2315703663 hasRelatedWork W1807622418 @default.
• W2315703663 hasRelatedWork W2021341693 @default.
• W2315703663 hasRelatedWork W2058514732 @default.
• W2315703663 hasRelatedWork W2076697195 @default.
• W2315703663 hasRelatedWork W2367828458 @default.
• W2315703663 hasRelatedWork W24430896 @default.
• W2315703663 hasRelatedWork W401598402 @default.
• W2315703663 hasRelatedWork W4237288479 @default.
• W2315703663 hasRelatedWork W4247602058 @default.
• W2315703663 hasRelatedWork W2784664999 @default.
• W2315703663 hasVolume "15" @default.
• W2315703663 isParatext "false" @default.
• W2315703663 isRetracted "false" @default.
• W2315703663 magId "2315703663" @default.
• W2315703663 workType "article" @default.